FADS2 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
astrocyte	19 studies	33% ± 15%	Explore
oligodendrocyte precursor cell	9 studies	28% ± 10%	Explore
endothelial cell	5 studies	32% ± 16%	Explore
retinal ganglion cell	5 studies	38% ± 23%	Explore
neuron	5 studies	25% ± 7%	Explore
retinal pigment epithelial cell	4 studies	30% ± 10%	Explore
erythroblast	4 studies	30% ± 5%	Explore
fibroblast	4 studies	23% ± 4%	Explore
GABAergic neuron	4 studies	24% ± 4%	Explore
glutamatergic neuron	4 studies	30% ± 8%	Explore
adipocyte	3 studies	32% ± 20%	Explore
megakaryocyte-erythroid progenitor cell	3 studies	48% ± 4%	Explore
oligodendrocyte	3 studies	20% ± 2%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
brain	8 studies	20% ± 3%	Explore
liver	3 studies	32% ± 4%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
brain	100%	10339.18	2640 / 2642	100%	217.47	703 / 705
adrenal gland	100%	43189.77	258 / 258	84%	86.27	194 / 230
prostate	99%	9572.96	243 / 245	68%	50.09	343 / 502
uterus	99%	8835.76	168 / 170	69%	42.27	315 / 459
liver	88%	8359.23	200 / 226	69%	52.34	279 / 406
lung	86%	3568.45	495 / 578	64%	32.13	740 / 1155
ovary	73%	2999.41	131 / 180	62%	28.01	265 / 430
breast	46%	1439.58	212 / 459	64%	61.44	716 / 1118
skin	63%	8979.37	1136 / 1809	46%	27.85	219 / 472
intestine	70%	2139.06	672 / 966	35%	14.22	183 / 527
esophagus	67%	2124.10	964 / 1445	35%	15.32	64 / 183
blood vessel	98%	5912.00	1313 / 1335	0%	0	0 / 0
bladder	52%	2365.57	11 / 21	43%	24.76	217 / 504
kidney	55%	1405.53	49 / 89	31%	8.52	277 / 901
tonsil	0%	0	0 / 0	82%	44.06	37 / 45
stomach	40%	1080.39	143 / 359	35%	12.69	99 / 286
adipose	68%	2533.33	816 / 1204	0%	0	0 / 0
heart	61%	1611.58	527 / 861	0%	0	0 / 0
pancreas	10%	194.84	33 / 328	48%	14.02	85 / 178
thymus	42%	884.01	272 / 653	14%	3.95	83 / 605
lymph node	0%	0	0 / 0	55%	13.55	16 / 29
spleen	37%	768.23	88 / 241	0%	0	0 / 0
peripheral blood	29%	3088.96	271 / 929	0%	0	0 / 0
eye	0%	0	0 / 0	11%	2.49	9 / 80
muscle	4%	69.62	34 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_1900409	Biological process	positive regulation of cellular response to oxidative stress
GO_0002538	Biological process	arachidonic acid metabolite production involved in inflammatory response
GO_0006636	Biological process	unsaturated fatty acid biosynthetic process
GO_0043651	Biological process	linoleic acid metabolic process
GO_0006629	Biological process	lipid metabolic process
GO_0036109	Biological process	alpha-linolenic acid metabolic process
GO_0005886	Cellular component	plasma membrane
GO_0016020	Cellular component	membrane
GO_0005789	Cellular component	endoplasmic reticulum membrane
GO_0016717	Molecular function	oxidoreductase activity, acting on paired donors, with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water
GO_0016213	Molecular function	linoleoyl-CoA desaturase activity
GO_0004768	Molecular function	stearoyl-CoA 9-desaturase activity

IV. Literature review

[source]

Gene name	FADS2
Protein name	Alternative protein FADS2 Fatty acid desaturase 2 Acyl-CoA 6-desaturase (EC 1.14.19.3) (Delta(6) fatty acid desaturase) (D6D) (Delta(6) desaturase) (Delta-6 desaturase) (Fatty acid desaturase 2)
Synonyms
Description	FUNCTION: Involved in the biosynthesis of highly unsaturated fatty acids (HUFA) from the essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3) precursors, acting as a fatty acyl-coenzyme A (CoA) desaturase that introduces a cis double bond at carbon 6 of the fatty acyl chain. Catalyzes the first and rate limiting step in this pathway which is the desaturation of LA (18:2n-6) and ALA (18:3n-3) into gamma-linoleate (GLA) (18:3n-6) and stearidonate (18:4n-3), respectively . Subsequently, in the biosynthetic pathway of HUFA n-3 series, it desaturates tetracosapentaenoate (24:5n-3) to tetracosahexaenoate (24:6n-3), which is then converted to docosahexaenoate (DHA)(22:6n-3), an important lipid for nervous system function (By similarity). Desaturates hexadecanate (palmitate) to produce 6Z-hexadecenoate (sapienate), a fatty acid unique to humans and major component of human sebum, that has been implicated in the development of acne and may have potent antibacterial activity . It can also desaturate (11E)-octadecenoate (trans-vaccenoate, the predominant trans fatty acid in human milk) at carbon 6 generating (6Z,11E)-octadecadienoate (By similarity). In addition to Delta-6 activity, this enzyme exhibits Delta-8 activity with slight biases toward n-3 fatty acyl-CoA substrates (By similarity). .
Accessions	L8E950 ENST00000257261.10 [O95864-2] E5RGD8 ENST00000517312.5 ENST00000521849.5 [O95864-3] E5RHL3 ENST00000278840.9 [O95864-1] O95864 ENST00000522056.5 [O95864-4] ENST00000517839.1 ENST00000518606.5 E5RGZ5

FADS2 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review